Podcast Episodes
Back to Search
Barclays Miami: Teva CEO Richard Francis talks about the company's emphasis on developing innovative medicines - including two recent financial deals to speed up development of IL-15 and TL1A
He discusses the company's third year in a row of revenue growth, and the new products that have helped Teva get there. Plus, a potential near-term a…
6 months ago
Barclays Miami: Latigo Bio aims to have a best-in-class Nav1.8 - a new class of medicines for pain that is the biotech sector's answer to the challenges that are presented by opioids
CEO Nima Farzan explains the science behind Nav1.8, why he believes Latigo's asset could be best in class, and the status of the company's developmen…
6 months ago
Barclays Miami: Arvinas will have an update next week for its LRRK2 targeting PROTAC for Parkinson's. The new CEO previews that and talks other targets they are working on
Randy Teel updates us on effectors to find a commercialization partner for the ER degrading PROTAC that is in front of FDA right now with a June 5 de…
6 months ago
Barclays Miami: Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now
President and CEO Kathy Dong describes the function of SIRPs and how Electra is targeting them with antibodies. Plus, an overview of the company's pr…
6 months ago
Barclays Miami: enGene is looking to have pivotal data and to file for its non-viral delivered gene therapy for bladder cancer this year
CEO Ron Cooper describes why you need an alternative to virally delivered products for indications like bladder cancer. Plus, previewing a data updat…
6 months ago
Barclays Miami: Barclays' Chair and Co-Head of Global Biopharma Investment Banking Jim Birchenough shares his take on the sector, M&A, and the IPO environment
He believes that the sector's fundamentals are strong and that M&A, which played a central role in boosting biotech last year, can keep up in 2026. P…
6 months ago
Quell Tx believes that restoring immune balance rather than entirely depleting immune cells is key for many autoimmune conditions - its CAR-Treg initiated a phase 1/2 in RA & Systemic Sclerosis today
CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addi…
6 months, 1 week ago
Protagonist Therapeutics has two medicines in front of FDA right now - we discuss the expertise in peptide based drug development that has enabled them to get to this point
CEO Dinesh Patel and Chief Discovery Officer Ashok Bhandari walk us through the company's R&D expertise, and we discuss programs covering IL-23, IL-1…
6 months, 3 weeks ago
Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - leveraging this, the company believes it has its own best in class insulin
CEO Sarah Howell discusses three key aspects of the business: helping with reformulation, its own proprietary insulin products, and developing oral p…
6 months, 4 weeks ago
NewLimit is using epigenetic reprogramming to bring cells back to a younger and healthier state, thus tackling age related disease
Co-Founder & President Jacob Kimmel describes the science behind how this works, and the enormous amount of work that goes into choosing which transc…
6 months, 4 weeks ago